RxDoctor Payments Data

Doran Spencer, MD

Ophthalmology · la Jolla, CANPI 1053670810

Payments from drug & device makers

$32,595in general payments, 2019–2025

Across 73 payments — averaging $446.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$13K
  • Novartis$10K
  • Eyepoint US, Inc.$4K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Regeneron$1K
  • Regeneron Healthcare Solutions, Inc.$824
  • plus $2K from 10 others

What the payments were for

  • Consulting fees$6,11561%
  • Speaking & faculty fees$4004%
  • Food & beverage$3,43535%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,595 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$192,863
Medicare patients
108
Services billed
1,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium17$5,949
ValacyclovirValacyclovir Hcl47$5,243
Prednisolone Acetate150$4,842
Difluprednate31$2,825
MethotrexateMethotrexate Sodium59$2,216
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat69$1,019
Timolol Maleate28$806
Atropine Sulfate19$446
Brimonidine Tartrate49$340
Ketorolac Tromethamine12$289
ErythromycinErythromycin Base14$254
Prednisone19$194
Latanoprost16$185
Folic Acid13$178
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$1,500$5,94917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →